JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cawley, T. J.
Right arrow Articles by Luthin, G. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cawley, T. J.
Right arrow Articles by Luthin, G. R.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ATROPINE
*CLOZAPINE
*FLUPHENAZINE

Effect of chronic neuroleptic treatment on central and peripheral muscarinic receptors

TA Cawley , TJ Shickley, MR Ruggieri and GR Luthin

Department of Physiology and Biophysics, Hahnemann University, Philadelphia, Pennsylvania.

The regulation of muscarinic acetylcholine receptor (MAChR) subtypes in rat striatum, bladder and heart was examined following a 14-day administration of neuroleptics (clozapine or fluphenazine), anticholinergics (atropine) or a combination of anticholinergics and neuroleptics. Levels of MAChRs were ascertained by the use of immunoprecipitation and radioligand binding. The combined treatment of fluphenazine and atropine produced an increase in all MAChR subtype levels in striatum with m1 receptor levels having the largest increase (270%) from control. A significant increase (105%) was also seen striatal in m2 receptor levels. Residual muscarinic receptor levels, representing the m3 and m4 subtypes, were increased (72%) to a lesser degree above control. Fluphenazine treatment alone increased levels of the m2 MAChR, whereas clozapine administration had no significant effect on levels of any MAChR subtype in this tissue. Administration of the cholinergic antagonist, atropine, showed a significant increase (89%) in the striatal m1 MAChR subtype. Of the MAChRs found in rat bladder and rat heart, the m2 subtype has been shown to be the most abundant. Results from the rat bladders indicated a reduction (50%) in muscarinic antagonist binding that was limited to the fluphenazine treatment group. In heart, atropine treatment alone produce a slight increase (ca. 10%) in receptor binding. No significant effect on muscarinic receptor levels was seen with the other treatment groups. These data demonstrate that there are differences in muscarinic receptor level modulation between central and peripheral tissues.

Volume 267, Issue 1, pp. 134-139, 10/01/1993
Copyright © 1993 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
M. A. Pontari, A. S. Braverman, and M. R. Ruggieri Sr.
The M2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunction
Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2004; 286(5): R874 - R880.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
T. J. Raedler, M. B. Knable, D. W. Jones, R. A. Urbina, J. G. Gorey, K. S. Lee, M. F. Egan, R. Coppola, and D. R. Weinberger
In Vivo Determination of Muscarinic Acetylcholine Receptor Availability in Schizophrenia
Am J Psychiatry, January 1, 2003; 160(1): 118 - 127.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1993 by the American Society for Pharmacology and Experimental Therapeutics.